Medical Consortium for Screening Upper Gastrointestinal Cancers With Magnetically Controlled Capsule Gastroscopy

Status

UNKNOWN

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT04032353

Enrollment

10000

Registered

2019-07-25

Start date

2018-12-31

Completion date

2020-03-01

Last updated

2019-07-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cancer of Esophagus, Cancer of Stomach, Capsule Endoscopy, Health Policy

Brief summary

The aim of our study was to demonstrate the efficacy and feasibility of the medical consortium for screening upper gastrointestinal cancers with magnetically controlled capsule gastroscopy.

Detailed description

In this study, the investigators designed a propective cohort study to evaluate the the efficacy and feasibility of medical consortium for screening upper gastrointestinal cancers (MCSC) with magnetically controlled capsule gastroscopy (MCCG).

Interventions

OTHERMedical Consortium

subjects received intensive follow-up by coordinators according to the predifined protocol of MCSC

Study design

Allocation

Intervention model

SINGLE_GROUP

Primary purpose

SCREENING

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to 80 Years

Healthy volunteers

Inclusion criteria

* asymptomatic subjects undergong magnetically controlled capsule gastroscopy for health checkup in medical consotium; * subjects able to give informed consent

Exclusion criteria

* suspected or known intestinal stenosis, obstruction, or fistula; * inoperability of refusal to accept any abdominal surgery; * dysphagia or gastric paralysis; * previous history of gastrointestinal disease; * with pacemaker, implanted-cardiac defibrillator or other implanted electromedical devices; * need for standard magnetic resonance imaging examination within seven days after swallowing the MCCG, unless the capsule is confirmed to have been excreted; * other factors that are not suitable for inclusion evaluated by medical stuff

Design outcomes

Primary

Measure	Time frame
the incidence of upper gastrointestinal cancers, including gastric cancer and esophageal cancer.	12 months

Secondary

Measure	Time frame
tthe focal lesions of upper gastrointestinal tract	12 months

Other

Measure	Time frame	Description
adverse events	12 months	safety assessment

Countries

China

Contacts

Primary ContactYanqing Li, PhD, MD

liyanqing@sdu.edu.cn86-531-82169236

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026